reports
TELA Bio to Announce First Quarter 2025 Financial Results
TELA Bio to Announce First Quarter 2025 Financial Results MALVERN, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2025 financial results on Thursday, May 8, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. First Quarter Earnings Conference Call and Webcast DetailsInvestors...
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham ...
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference AUSTIN, TX and DURHAM, NC, April 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will present at and participate in one-on-one meetings at the 24th Annual Needham Virtual Healthcare Conference, taking place April 7–10...
TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® P...
TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® PRS for Plastic and Reconstructive Surgery The OviTex PRS portfolio now includes a larger option than any human acellular dermal matrix product on the market MALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: TELA), a commercial-stage medical technology company focused on advancing soft-tissue reconstruction solutions, today announced the U.S. launch of larger sizes of OviTex PRS Reinforced Tissue Matrix, the only tissue-based device reinforced with polymer suture embroidery specifically engineered for plastic...
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Resu...
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights – Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn’s and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-class blocking antibody to DR3, the receptor for TL1A; data demonstrated favorable safety profile, full receptor occupancy, lack of DR3 agonism – – SL-325 advances toward Phase 1; on track for IND filing in the third quarter of 2025 – – Cash balance of approximately $73.0 million as of D...
CPS Announces $65.0 Million Securitization of Residual Interests
CPS Announces $65.0 Million Securitization of Residual Interests LAS VEGAS, Nevada, March 20, 2025 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced the closing of a $65.0 million securitization of residual interests from previously issued securitizations. In the transaction, a qualified institutional buyer purchased $65.0 million of asset-backed notes secured by an 80% interest in a CPS majority owned affiliate (“MOA”) that owns the residual interests in five CPS securitizations issued from October 2023 through September 2024. ...
TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results
TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered revenue of $17.6 million in the fourth quarter and $69.3 million for the full year 2024, representing growth of 4% and 19%, respectively, over the corresponding periods of 2023;Increased demand for O...
Stitch Fix Announces Second Quarter of Fiscal Year 2025 Financial Resu...
Stitch Fix Announces Second Quarter of Fiscal Year 2025 Financial Results SAN FRANCISCO, March 11, 2025 (GLOBE NEWSWIRE) -- Stitch Fix, Inc. (NASDAQ: SFIX), the leading online personal styling service, today announced its financial results for the second quarter of fiscal year 2025, ended February 1, 2025. “Our team delivered another strong quarter, once again exceeding our expectations as we further advanced our transformation strategy,” said Matt Baer, CEO, Stitch Fix. “Our clients are responding to the improvements we’ve made to our experience, including the increased newness in our a...
TELA Bio to Announce Fourth Quarter and Full Year 2024 Financial Resul...
TELA Bio to Announce Fourth Quarter and Full Year 2024 Financial Results MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 20, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Fourth Quarter Earnings Conference ...
- Dave Nicoski
- Ross LaDuke
PMT PENNYMAC MORTGAGE INVESTMENT TRUST
BKD BROOKDALE SENIOR LIVING INC.
WBA WALGREENS BOOTS ALLIANCE INC
PLOW DOUGLAS DYNAMICS INC.
NSP INSPERITY INC.
NEU NEWMARKET CORPORATION
MDLZ MONDELEZ INTERNATIONAL INC. CLASS A
INTC INTEL CORPORATION
HSY HERSHEY COMPANY
DLTR DOLLAR TREE INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BAX BAXTER INTERNATIONAL INC.
SBL SAFE BULKERS INC.
CYH COMMUNITY HEALTH SYSTEMS INC.
LKO LAKES OIL N.L.
AWK AMERICAN WATER WORKS COMPANY INC.
CWT CALIFORNIA WATER SERVICE GROUP
TNC TENNANT COMPANY
NGVT INGEVITY CORPORATION
KALV KALVISTA PHARMACEUTICALS
SSTI SHOTSPOTTER
VIAC VIACOMCBS INC. CLASS B
STTK SHATTUCK LABS
CSTM CONSTELLIUM SE CLASS A
LUNG PULMONX
BBWI BATH & BODY WORKS INC
UWMC UWM HLDGS CORP
UDMY UDEMY INC
AMGN AMGEN INC
NYMT NEW YORK MORTGAGE TRUST INC.
HSHP HIMALAYA SHIPPING LTD.
PCH PICOMAT PLASTIC JSC
CPS Announces Fourth Quarter and Full Year 2024 Earnings
CPS Announces Fourth Quarter and Full Year 2024 Earnings Revenues of $105.3 million for the fourth quarter and $393.5 million for 2024Net income of $19.2 million, or $0.79 per diluted share for 2024Total portfolio balance of $3.491 billion, highest in company historyNew contract purchases of $1.682 billion for the full year 2024 LAS VEGAS, NV, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced earnings of $5.1 million, or $0.21 per diluted share, for its fourth quarter ended December 31, 2024. Revenues for the four...
CPS to Host Conference Call on Fourth Quarter 2024 Earnings
CPS to Host Conference Call on Fourth Quarter 2024 Earnings LAS VEGAS, Nevada, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced that it will hold a conference call on Wednesday, February 26, 2025 at 1:00 p.m. ET to discuss its fourth quarter 2024 operating results. Those wishing to participate can pre-register for the conference call at the following link . Registered participants will receive an email containing conference call details for dial-in options. To avoid delays, we encourage participants to dial into t...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 7,200 shares of its common stock to thirteen newly-hired employees, with a grant date of February 19, 2025 (the "Grant Date"). The restricted stock units were grante...
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicol...
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025 – SL-325 is a high-affinity DR3 blocking antibody being developed for the treatment of inflammatory bowel disease (IBD); No evidence of toxicity or residual agonism observed in non-human primate toxicology study – – SL-325 receptor occupancy (RO) and pharmacokinetic (PK) profile observed suggestive of extended dosing intervals; IND filing expected in the third quarter of 2025 – AUSTIN, TX & ...
Stitch Fix Announces Date for Second Quarter 2025 Financial Results an...
Stitch Fix Announces Date for Second Quarter 2025 Financial Results and Conference Call SAN FRANCISCO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Stitch Fix, Inc. (NASDAQ:SFIX), the leading online personal styling service, today announced that it will release financial results for its second quarter fiscal year 2025 ended February 1, 2025 after market close on Tuesday, March 11, 2025. Following this, Stitch Fix will hold a conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results and outlook. The call will be hosted by Matt Baer, CEO, and David Aufderhaar, CFO. A live webcas...
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of...
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025 AUSTIN, TX & DURHAM, NC, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced an upcoming oral presentation at the 20th Congress of ECCO in Inflammatory Bowel Diseases 2025 being held i...
Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s a...
Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis Congress AUSTIN, TX and DURHAM, NC, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced an upcoming poster presentation at the 2025 Crohn’s and Colitis Congress being held in San Francisco, California from February 6–8, 2025. Presentation DetailsFormat: Post...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Jan. 24, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 4,000 shares of its common stock to seven newly-hired employees, with a grant date of January 21, 2025 (the "Grant Date"). The restricted stock units were granted pu...
CPS Announces $442.4 Million Senior Subordinate Asset-Backed Securitiz...
CPS Announces $442.4 Million Senior Subordinate Asset-Backed Securitization LAS VEGAS, Nevada, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) announced the closing of its first term securitization in 2025 on Wednesday January 22, 2025. The transaction is CPS's 54th senior subordinate securitization since the beginning of 2011 and the 37th consecutive securitization to receive a triple “A” rating from at least two rating agencies on the senior class of notes. In the transaction, qualified institutional buyers purchased $442.4 mi...
Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan He...
Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference AUSTIN, TX and DURHAM, NC, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will present a corporate update and participate in one-on-one meetings at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Franc...
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Mi...
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025 AUSTIN, TX and DURHAM, NC, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced a corporate update and highlighted upcoming key milestones anticipated in 2025. “We have made considerable progress in the development of our potential first-in-class DR3 bl...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.